<DOC>
	<DOCNO>NCT01380756</DOCNO>
	<brief_summary>This study AMG 900 conduct two part : dose escalation dose expansion . The dose escalation part study aim evaluate safety , tolerability PK ( pharmacokinetics ) oral AMG 900 subject acute myeloid leukemia . Up 93 subject may enrol dose escalation . The dose expansion part study consist 20 subject acute myeloid leukemia . The dose AMG 900 dependent upon data dose escalation part study .</brief_summary>
	<brief_title>Study Evaluating Orally Administered AMG 900 Adult Subjects With Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Men woman â‰¥ 18 year old Pathologically document , definitively diagnose AML fail standard treatment standard therapy available subject refuse standard therapy Must consent undergo bone marrow biopsy per schedule assessment White blood cell great 20,000 uL History active central nervous system leukemia Prior allogeneic bone marrow transplant Subject available protocolrequired study visit procedures Other Inclusion/ Exclusion Criteria may apply qualify enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Amgen</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Aurora kinase inhibitor</keyword>
	<keyword>Open label</keyword>
	<keyword>Oncology</keyword>
	<keyword>Hematology</keyword>
</DOC>